BLPH News and Press, Bellerophon Therapeutics Inc. From 03/23/20

Gainers: Jiayin Group (NASDAQ: JFIN ) +182% . More news on: Jiayin Group Inc., Hoth Therapeutics, Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...

AG Mortgage Investment Trust (NYSE: MITT )  -43%  after entering into forbearance talks . More news on: AG Mortgage Investment Trust, Inc., Bellerophon Therapeutics, Inc., Micro Focus International plc, Stocks on the move, , Read more ...

Gainers: Bellerophon Therapeutics (NASDAQ: BLPH ) +407% . More news on: Bellerophon Therapeutics, Inc., Hepion Pharmaceuticals, Inc., Penn National Gaming, Inc., Stocks on the move, , Read more ...

4 Coronavirus Penny Stocks To Watch Before Next Week It’s safe to say the coronavirus penny stocks are a major topic of conversation right now. It seems like the more we try to find a reason to avoid it, the more it becomes a focus. But for traders, that hasn’t been a bad thing...

Bellerophon Therapeutics (NASDAQ: BLPH ) +472% on FDA nod for emergency use of INOpulse for Covid-19. More news on: Bellerophon Therapeutics, Inc., Rand Capital, GenMark Diagnostics, Inc., Stocks on the move, Read more ...

WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency expan...

Based on FDA feedback, Bellerophon Therapeutics ( BLPH   +12% ) has set the key aspects of its planned Phase 3 clinical trial evaluating INOpulse for the treatment of pulmonary hypertension associated with pulmonary fibrosis. More news on: Bellerophon Therapeutics, Inc., Healthcare ...

WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings with the U.S. Food ...

Under Priority Review and Breakthrough Therapy status, the FDA approves privately held Boehringer Ingelheim's Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). More news o...

Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...